Plunging Johnson & Johnson Vaccine Supply Dents State Inoculation Efforts

With deliveries from Johnson & Johnson set to fall 86 percent, a White House official warned that the vaccine would be scarce until a troubled Baltimore plant gains regulatory approval.

WASHINGTON — Supplies of Johnson & Johnson’s one-dose coronavirus vaccine will be extremely limited until federal regulators approve production at a Baltimore manufacturing plant with a pattern of quality-control lapses, the White House’s pandemic response coordinator said on Friday. With allocations of the company’s vaccine set to plunge by 86 percent next week, governors across the country warned that the loss of supplies they had been counting on would set back their vaccination drives. Federal officials said Moderna and Pfizer-BioNTech, the other two federally authorized vaccine manufacturers, could make up some of the shortfall. They also pointed out that some states were not currently using all the vaccine allocated to them.